Table 1 Comparison of baseline clinical characteristics of patients with newly diagnosed metastatic colorectal cancer stratified by pre-treatment lymphocyte-to-monocyte ratio (LMR)
Characteristic | LMR < 3.11 [cases (%)] | LMR ≥ 3.11 [cases (%)] | P value |
|---|---|---|---|
Total | 216 | 272 | |
Gender | 0.817 | ||
Male | 119 (55.1) | 147 (54.0) | |
Female | 97 (44.9) | 125 (46.0) | |
Age (years) | 0.802 | ||
<60 | 139 (64.4) | 178 (65.4) | |
≥60 | 77 (35.6) | 94 (34.6) | |
ECOG performance status | 0.013 | ||
<2 | 126 (58.3) | 188 (69.1) | |
≥2 | 90 (41.7) | 84 (30.9) | |
Site of primary tumor | 0.907 | ||
Colon | 114 (52.8) | 145 (53.3) | |
Rectum | 102 (47.2) | 127 (46.7) | |
No. of metastatic sites | <0.001 | ||
≤2 | 157 (72.7) | 118 (43.4) | |
>2 | 59 (27.3) | 154 (56.6) | |
Tumor differentiation | <0.001 | ||
Well or moderate | 163 (75.5) | 120 (44.1) | |
Poor | 53 (24.5) | 152 (55.9) | |
Pre-chemotherapy ALC (×109/L) | |||
<2.70 | 122 (56.5) | 107 (39.3) | |
≥2.70 | 94 (43.5) | 165 (60.7) | |
Pre-chemotherapy AMC (×109/L) | <0.001 | ||
<0.55 | 57 (26.4) | 128 (47.1) | |
≥0.55 | 159 (73.6) | 144 (52.9) | |